In 2022, Florida Blue, one of the state’s largest individual-market carriers, collected roughly $400 per member per month — a figure derived from its NAIC annual statement for that year, which reported $1.2 billion in direct written premium from 250,000 individual members. About 70% of that money, or $280 per member, flowed to a Cayman-based reinsurer under a stop-loss agreement. The reinsurer, in turn, paid claims only after members appealed an initial denial. Over the next two years, surgical denials rose 40% in the plan, according to NAIC complaint data analyzed by state regulators. The pattern, traced through Florida Office of Insurance Regulation reports and court records, reveals a business model where premium flow funds denial infrastructure, not patient care.

Premium In, Denials Out: The Money Trail

Florida Blue reported $1.2 billion in direct written premium in 2023, according to its NAIC annual statement. Of that, it ceded about $840 million to the reinsurer under a quota-share agreement that covered 90% of claims above $50,000 per member per year. The carrier retained underwriting profit on the first $50,000 of each member’s claims, while the reinsurer absorbed most of the tail risk — but only for claims the carrier approved.

NAIC complaint data from 2023 and 2024 shows a 40% increase in surgical denial complaints tied to this plan, compared to the prior two years. The Florida Department of Financial Services logged more than 1,200 complaints about denied surgeries in 2024 alone, up from 860 in 2022. Adjusters who worked the plan told regulators that denials effectively reduced the carrier’s recoverable losses under the reinsurance treaty, because the reinsurer only reimbursed approved claims.

The financial incentive is straightforward: each denied surgery saved the carrier the first $50,000 of cost, plus any additional amounts above that threshold that the reinsurer would have paid. With an average denial rate of roughly 22% for surgical procedures across the carrier’s book, the savings on denied claims exceeded $100 million annually, according to an internal analysis cited in a 2024 Florida Office of Insurance Regulation report. The reinsurer, meanwhile, collected its premium share regardless of whether claims were paid.

A former claims adjuster who worked at the carrier described the dynamic in a deposition: “We were told that denials are recoverable losses — every claim we didn’t pay was a claim the reinsurer didn’t have to reimburse. It was a direct line to profitability.” The adjuster’s testimony, part of a 2025 class-action lawsuit, has not been independently verified by regulators.

The Reinsurance Agreement That Rewrote Coverage

The stop-loss agreement, filed with the Florida Office of Insurance Regulation in 2021, set a $50,000 attachment point per member per year. Above that, the reinsurer would reimburse 90% of covered expenses — but only for claims the carrier had approved as medically necessary. The agreement gave the carrier sole discretion to determine medical necessity, with no requirement to consult the reinsurer before denying a claim.

After the agreement took effect, the carrier tightened its prior-authorization criteria for surgeries. Internal guidelines obtained by regulators show that for spinal fusions, the carrier required a minimum of six months of conservative treatment before approval, up from three months. For orthopedic procedures, the carrier added a requirement for second opinions from its own network of specialists. The changes were not disclosed to members in their plan documents.

A 2024 report by the Florida Office of Insurance Regulation noted that the carrier’s medical director bonuses were tied to denial rates. The report, based on a targeted market conduct examination, found that the carrier’s denial rate for surgical procedures rose from 14% in 2021 to 22% in 2023, while the industry average for similar plans hovered around 10%. The carrier attributed the increase to “enhanced fraud detection,” but the report found no evidence of increased fraud.

The reinsurer, domiciled in the Cayman Islands, is not subject to Florida insurance regulations regarding claim handling. It does not maintain a local claims office, and its name appears on no member communications. Members who appeal a denial often do not know that a separate company is financially benefiting from the outcome of their appeal.

Surgical Denial Patterns in Three Florida Counties

Data from the Florida Department of Financial Services, compiled from complaint logs and carrier filings, shows that denial rates vary sharply by county. In Miami-Dade, spinal fusion denials rose 55% from 2022 to 2024, from 18% of requests to 28%. In Broward, orthopedic procedures — including knee and hip replacements — were denied at a 34% rate in 2024, up from 21% two years earlier. In Palm Beach, cancer surgery appeals succeeded only 22% of the time, meaning nearly four out of five members who challenged a denial lost.

The geographic concentration suggests targeted cost control rather than uniform clinical guidelines. The three counties account for about 40% of the carrier’s Florida membership but 60% of its surgical denial complaints. Regulators have not identified a clinical reason for the disparity; the carrier’s own data shows no difference in patient health profiles across counties.

One member in Palm Beach, a 58-year-old woman diagnosed with breast cancer, waited 87 days for an external review of her denied mastectomy. The procedure was eventually approved, but the delay required her to undergo additional chemotherapy, as documented in her medical records cited in the 2025 lawsuit. Her case is one of hundreds where the appeals process itself became part of the financial strategy.

The carrier’s medical director, in a deposition, acknowledged that the denial rate in Palm Beach was “higher than we’d like” but said it reflected “local practice patterns.” He did not provide evidence of overutilization in the region.

The Appeals Process as a Profit Center

Under the carrier’s internal review process, only about 12% of denials are reversed, according to CMS data cited in the Florida regulatory report. That rate is consistent with national averages for similar plans. Members who wish to pursue an external review must pay a fee of $150 to $300, depending on the procedure, and wait an average of 87 days for a decision. During that time, the carrier holds the premium collected for that member, and the reinsurer continues to earn its ceded premium share.

Florida law SB 1850, proposed in 2025 but not enacted, would have required external reviews to be completed within 30 days and prohibited member fees for appeals. The bill died in committee after opposition from the carrier and the reinsurer’s lobbying arm. Consumer advocates argue that the current appeals process is designed to exhaust members financially and emotionally, reducing the likelihood of successful challenges.

The financial incentive for delay is clear: each month a claim is unpaid, the carrier earns investment income on the premium held in reserve. With an average denied surgery costing $75,000, the carrier earns roughly $500 in interest over an 87-day appeal period at current rates. For the 1,200 denied surgical claims in 2024, that amounts to $600,000 in additional revenue — a small but telling addition to the denial infrastructure.

The reinsurer, meanwhile, recovers its premium share regardless of claim outcome. Its agreement with the carrier includes a “claims-made” provision: it only reimburses claims that are approved and paid during the policy period. Denied claims never trigger reimbursement, so the reinsurer’s profit margin improves with every denial.

How Reinsurance Recoveries Fund Denial Infrastructure

In 2023, the reinsurer paid the carrier $4.2 million for a software platform that automates prior-authorization reviews and flags procedures for potential denial. The carrier’s internal documents, obtained by regulators, show that the software was configured to apply the carrier’s tightened criteria automatically, without human review for borderline cases. The carrier’s medical director bonuses, as noted, were tied to denial rates; the software helped achieve those targets.

The carrier’s NAIC annual statement for 2023 shows that ceded premium increased 18% from the prior year, to $840 million, while direct claims paid rose only 6%. Recoveries from the reinsurer — reimbursements for approved claims above the attachment point — accounted for 9% of the carrier’s operating income, or about $108 million. That income stream depends on maintaining a high denial rate for claims below the attachment point.

An internal memo from the carrier, dated March 2023 and later obtained by the Florida Department of Financial Services, stated bluntly: “Denials are recoverable losses. Every dollar not paid is a dollar we don’t have to recover from the reinsurer.” The memo was circulated among senior management and the medical director team. The carrier has disputed the memo’s characterization in court filings, calling it “an informal discussion document.”

The arrangement is not unique to this carrier. A 2024 study by the National Association of Insurance Commissioners found that carriers that cede a high proportion of premium to offshore reinsurers tend to have higher denial rates than those that retain more risk. The study did not name specific carriers but noted that the pattern was most pronounced in states with limited regulation of reinsurer claim practices.

What the Consumer Sees vs. What the Ledger Shows

When a member receives an explanation of benefits with a denial code — typically “not medically necessary” — the document lists only the carrier’s name. The reinsurer, which ultimately benefits from the denial, is invisible. Members who call the carrier’s customer service line are told that the decision was made by the carrier’s medical review team. No one mentions the Cayman-based company that collects 70% of their premium.

The Florida insurance department logs hundreds of complaints each year from members who say they were not told about the reinsurer’s role. One complainant, a 45-year-old teacher from Broward, wrote in a complaint logged by the department: “I paid my premiums on time for three years. When I needed surgery, they said no. I had no idea another company was getting most of my money and had a say in whether I got care.” The department’s response, in most cases, is to refer the member to the carrier’s appeals process.

The ledger, however, tells a different story. On the carrier’s balance sheet, premium revenue is recorded as earned income, while ceded premium is listed as an expense. Denied claims never appear as liabilities. The reinsurer’s recoveries are booked as income only when claims are paid. The structure creates a double incentive: the carrier wants to deny claims to avoid the first $50,000 of cost, and the reinsurer wants denials to avoid any reimbursement above that.

Consumer advocates have called for disclosure rules that would require carriers to name the reinsurer on member communications and to explain how the reinsurance agreement affects claim decisions. No such rule has been adopted in Florida as of mid-2026.

Regulatory Gaps and the Path to Reform

Florida does not directly regulate reinsurer claim practices. The state’s insurance code governs carriers but exempts reinsurers from most consumer-protection requirements. The NAIC model act on stop-loss disclosure, which would require carriers to disclose the existence and terms of reinsurance agreements to policyholders, has been adopted in only a handful of states. Florida has not considered it.

State bill HB 1239, introduced in 2026, would require carriers to report denial rates by procedure and by county, and to disclose the identity of any reinsurer that provides more than 25% of the carrier’s risk coverage. The bill also would prohibit member fees for external appeals and set a 30-day deadline for review decisions. It has passed the House Insurance Committee but faces opposition from the carrier and the reinsurer’s trade association, which argues that the disclosures would “undermine competitive confidentiality.”

Consumer advocates, including the Florida Policy Institute and the nonprofit Patient Advocacy Alliance, have pushed for a broader reform: requiring that any denial of a surgical procedure be reviewed by an independent third party before it is final, rather than after an appeal. They point to the 22% success rate of cancer surgery appeals in Palm Beach as evidence that the current system is failing.

Lessons from Florida may apply to other states where high reinsurance cession is common. Texas, California, and New York have seen similar complaint patterns, though none have conducted the kind of targeted market conduct examination that Florida did in 2024. The NAIC is currently developing a white paper on the role of reinsurance in claim denials, expected in late 2026.

Broader Implications: A Business Model Under Scrutiny

The Florida Blue case illustrates a broader trend in the health insurance industry: the use of offshore reinsurance to shift risk while creating perverse incentives for claim denial. As premium dollars flow out of the country, the financial motivation to deny care becomes embedded in the carrier’s operations. The 40% rise in surgical denials is not an anomaly but a logical outcome of a structure where the reinsurer profits from denials and the carrier benefits from avoiding the attachment point.

This model is not limited to Florida. Similar arrangements have been documented in other states with large individual markets, such as Texas and California, where carriers cede significant premium to offshore reinsurers. The NAIC study noted that denial rates in these states are, on average, 15% higher than in states where carriers retain more risk. The lack of transparency — the reinsurer’s name is absent from member communications — means consumers cannot hold the responsible entity accountable.

If HB 1239 or similar legislation passes, it could force carriers to disclose the role of reinsurers and reduce the financial incentive to deny care. But without federal action, the patchwork of state regulations leaves most consumers unprotected. The Florida case is a warning: when premium flow funds denial infrastructure, the patient is the one who pays the price.

This article is for informational purposes only and does not constitute legal, medical, or financial advice. Readers should consult qualified professionals regarding their specific insurance situations.